Analyst Price Targets — ALKS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 11:39 am | Douglas Tsao | H.C. Wainwright | $43.00 | $31.04 | StreetInsider | Alkermes (ALKS) PT Lowered to $43 at H.C. Wainwright |
| February 23, 2026 9:09 pm | — | Wolfe Research | $45.00 | $32.19 | TheFly | Alkermes initiated with an Outperform at Wolfe Research |
| October 28, 2025 5:16 pm | Akash Tewari | Jefferies | $56.00 | $30.75 | StreetInsider | Jefferies on Alkermes (ALKS) Earnings: 'Solid Q3 + FY guide raise' |
| October 27, 2025 11:49 am | — | Mizuho Securities | $45.00 | $29.76 | TheFly | Alkermes price target raised to $45 from $40 at Mizuho |
| October 23, 2025 10:29 am | David Amsellem | Piper Sandler | $45.00 | $31.09 | TheFly | Alkermes price target raised to $45 from $38 at Piper Sandler |
| October 22, 2025 6:48 pm | — | RBC Capital | $47.00 | $31.09 | TheFly | Alkermes price target raised to $47 from $45 at RBC Capital |
| September 26, 2025 9:22 am | Alkermes to Outperform | RBC Capital | $44.00 | $28.14 | TheFly | Alkermes upgraded to Outperform from Sector Perform at RBC Capital |
| September 9, 2025 11:20 am | — | Needham | $43.00 | $27.85 | TheFly | Alkermes price target lowered to $43 from $45 at Needham |
| September 9, 2025 10:16 am | Douglas Tsao | H.C. Wainwright | $46.00 | $27.77 | TheFly | Questions remain after Alkermes narcolepsy data, says H.C. Wainwright |
| September 2, 2025 8:40 pm | — | Wells Fargo | $44.00 | $29.40 | TheFly | Alkermes initiated with an Overweight at Wells Fargo |
Latest News for ALKS
Artisan Partners Limited Partnership grew its stake in shares of Alkermes plc (NASDAQ: ALKS) by 36.8% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,109,772 shares of the company's stock after purchasing an additional 567,965 shares during the period. Artisan Partners Limited Partnership
Alkermes (NASDAQ: ALKS) executives highlighted a "strong and eventful" 2025 and outlined a 2026 plan focused on expanding the company's commercial platform following its Avadel acquisition while advancing its orexin pipeline, led by alixorexton, into late-stage development. Management also announced a CEO transition, with longtime chief executive Richard Pops set to step down this summer and
ALKS beats Q4 earnings and revenue estimates, but shares fall 7%. The company announces a CEO transition plan.
While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alkermes (ALKS) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $1.04 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALKS.
U.S. House Trading
No House trades found for ALKS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.